跳至主要内容
临床试验/EUCTR2009-009467-59-BE
EUCTR2009-009467-59-BE进行中(未招募)不适用

Feasibility study of hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with stage III or only pleural stage IV ovarian carcinoma in first line therapy. - HIPEC-ovarian carcinoma

Institut Jules Bordet0 个研究点开始时间: 2010年1月20日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1. Histologically confirmed ovarian carcinoma or primary peritoneal carcinoma or Fallopian tube carcinoma.
  • 2. FIGO stage III disease or only pleural stage IV disease
  • 3. Age less than 65 years
  • 4. ECOG performance status 0-1.
  • 5. Adequate bone marrow, hepatic and renal functions.
  • 6. No serious cardiac or respiratory illness
  • 7. No major co morbidity such as diabetes or other condition that might hamper the postoperative recuperation.
  • 8. preoperative chemotherapy with carboplatinum-paclitaxel is recommended for lower surgical morbidity (3 courses).
  • 9. PCI (peritoneal carcinomatosis index) score < 21
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. metastatic disease in other sites than pleural
  • 2. age higher than 65 years
  • 3. ECOG PS 2 or higher
  • 4. serious cardiac or respiratory illness
  • 5. major co morbidity
  • 6. impaired bone marrow, hepatic and renal functions
  • 7. PCI score equal or higher than 21

研究者

发起方
Institut Jules Bordet

相似试验

Feasibility study of hyperthermic intraperitoneal... | 临床试验